Welcome to our dedicated page for Tandem Diabetes Care news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes Care stock.
Tandem Diabetes Care, Inc. (symbol: TNDM) is a leading medical device company committed to enhancing the lives of individuals with diabetes through continuous innovation and a customer-first approach. Based in San Diego, California, Tandem focuses on the design, development, and commercialization of advanced insulin pump technologies.
The company's flagship products include the t:slim X2™ insulin pump, noted for its unique ability to receive remote feature updates via a personal computer, and the t:flex® insulin pump, which is tailored for patients with higher insulin requirements. These devices are designed to offer users greater flexibility, control, and ease of use, significantly improving diabetes management.
In addition to these main products, Tandem has introduced the Mobi pump, a smaller, more discreet device, and is actively working on developing a tubeless pump to further enhance user convenience and experience. The company's product portfolio generates substantial revenue from both the insulin pumps themselves and the accompanying disposable infusion sets, which need regular replacement every 2 to 3 days.
Approximately 75% of Tandem's total revenue comes from the U.S. market, with the remaining sales derived from other developed countries. The company's strong focus on innovation and user experience has cemented its position as a trusted name in diabetes care.
For the latest updates and relevant information about Tandem Diabetes Care, Inc., including recent achievements, ongoing projects, financial performance, and strategic partnerships, stay tuned to our news section.
Note: This description is for informational purposes only and is not intended for product support or medical advice. In case of a medical emergency, please dial 911. For immediate assistance with Tandem products, contact the 24-hour customer support team at 877-801-6901, pressing 1 twice.
Tandem Diabetes Care (NASDAQ: TNDM) reported strong financial results for Q2 2021, with worldwide pump shipments up 81% to 33,817 units and sales rising 58% to $172.1 million. The gross margin increased to 54%, while operating income turned positive at $5.4 million. The company added 40% domestic pump shipments and 233% international growth, pushing adjusted EBITDA to $23.8 million. Cash reserves reached $545.3 million. Revised guidance for 2021 estimates sales between $670 million and $685 million, reflecting a growth of 34-37% year-over-year.
Tandem Diabetes Care (NASDAQ: TNDM) will present a company update at the UBS Genomics 2.0 and Medtech Innovations Summit on August 12, 2021, at 2:00 PM ET. The presentation will be available via a live webcast, with an archived recording accessible for 30 days thereafter. The link can be found on the Investor Center section of Tandem's website. Tandem focuses on improving the lives of people with diabetes through innovative medical devices, including their flagship product, the t:slim X2 insulin pump, which supports remote software updates and features integrated glucose monitoring.
Tandem Diabetes Care (NASDAQ: TNDM) is set to release its second quarter 2021 results on August 4, 2021, after market close. A conference call will follow at 4:30 PM ET to discuss financial and operational outcomes. Investors can join via a toll-free number or webcast. The company focuses on innovative insulin delivery solutions, with its flagship product being the t:slim X2™ insulin pump, which supports remote updates and integrated glucose monitoring.
Tandem Diabetes Care (NASDAQ: TNDM) recently showcased positive real-world data regarding its t:slim X2 insulin pump with Control-IQ technology at the American Diabetes Association's 81st Scientific Sessions. The findings indicate statistically significant glycemic improvements and enhanced quality of life for users, including diverse populations. Notably, disparities in glycemic outcomes by ethnicity were observed, but improvements were consistent across all groups. Key presentations highlighted the efficacy of Control-IQ in managing diabetes and its impact on users' daily lives.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) showcased successful real-world use data of its t:slim X2™ insulin pump with Control-IQ™ technology at the ATTD conference. Over 9,000 users experienced significant improvements in time in range (TIR) for diabetes management over 12 months. Dr. Jordan Pinsker emphasized the technology's real-world effectiveness and the positive impact on patients' quality of life. Additional studies indicated a median TIR of 73.6%, with high automation rates and low incidences of hypoglycemia, reflecting strong performance and user satisfaction with the device.
Tandem Diabetes Care, Inc. (TNDM) reported a strong first quarter of 2021, with worldwide pump shipments increasing 46% to 25,352 units and sales rising 44% to $141 million, compared to Q1 2020. Gross profit improved to $73.3 million, and Adjusted EBITDA reached $13.2 million. The company's net loss narrowed to $5 million from $14.9 million year-over-year. Tandem updated its 2021 sales guidance, now estimating $625-$640 million, marking a growth of 25-28% year-over-year. International sales are projected at $125-$130 million, reflecting a 50-56% increase.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced its participation in three upcoming virtual investor conferences. Management will provide updates during:
- BofA Securities 2021 Virtual Health Care Conference on May 12, 2021, at 5:00 PM ET
- Berenberg Conference USA 2021 on May 18, 2021, at 3:00 PM ET
- UBS Global Healthcare Virtual Conference on May 24, 2021, at 12:00 PM ET
These presentations will be webcast live and available for 30 days on the company's Investor Center website.
CeQur has completed an oversubscribed $115 million equity financing to support commercial plans for its insulin-delivery device, CeQur Simplicity. The funds will enhance market development, initiate a phased launch in 2021, and scale manufacturing. CeQur Simplicity is FDA cleared and CE-marked, designed to replace multiple daily injections for over 3 million Americans. Clinical studies show significant improvement in insulin regimen adherence and glycemic control. The device targets a $7.5 billion U.S. market, aiming to ease insulin delivery for diabetes patients globally.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is set to release its first quarter 2021 results after market close on May 5, 2021. A conference call will follow at 4:30 PM ET to discuss the financial and operational results. Shareholders and interested parties can access details via dial-in numbers or through a live webcast. Tandem Diabetes is known for its innovative insulin delivery solutions, particularly the t:slim X2™ insulin pump that features remote software updates and integrated continuous glucose monitoring.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced management will present a company update at two upcoming virtual investor conferences. The presentations are scheduled for the Barclays Global Healthcare Conference on March 10, 2021, at 3:00 PM ET and the Oppenheimer’s 31st Annual Healthcare Conference on March 17, 2021, at 2:30 PM ET. The updates will be webcast live, with an archive available for 30 days on Tandem's Investor Center website. This showcases Tandem's commitment to transparency and engagement with investors.
FAQ
What is the current stock price of Tandem Diabetes Care (TNDM)?
What is the market cap of Tandem Diabetes Care (TNDM)?
What is Tandem Diabetes Care, Inc. known for?
Where is Tandem Diabetes Care, Inc. located?
What are the main products of Tandem Diabetes Care, Inc.?
How do the t:slim X2™ insulin pump updates work?
What percentage of Tandem Diabetes Care's revenue comes from the U.S.?
Does Tandem Diabetes Care offer customer support?
What recent products has Tandem Diabetes Care introduced?
What materials are required to replace in Tandem's insulin pumps?
What is the unique feature of the t:flex® insulin pump?
How does Tandem Diabetes Care innovate in diabetes care?
